1.50432

LiChrosorb^® RP-8 (5 µm) HPLC Columns

L x I.D. 125 mm x 4 mm, Hibar^® RT HPLC Column

• Sinónimos: TM=["LiChrosorb"] C8 HPLC column
• UNSPSC Code: 41115709
• NACRES: SB.52

Propiedades

• product name: LiChrosorb^® RP-8 (5 µm) Hibar^® RT 125-4, suitable for HPLC
• material: stainless steel column
• Quality Level: 100
• agency: suitable for USP L7
• product line: LiChrosorb^®
• feature: endcapped: no
• parameter: 400 bar pressure; 60 °C max. temp.
• technique(s): HPLC: suitable; mass spectrometry (MS): suitable (Low)
• column L × I.D.: 12.5 cm × 4 mm
• matrix: fully porous particle
• matrix active group: C8 bonding phase
• particle size: 5 μm
• pore size: 100 Å pore size
• operating pH range: 2-7.5
• separation technique: reversed phase; supercritical fluid (SFC)
• storage temp.: no temp limit

Descripción

General description

HPLC column

LiChrosorb^® RP-8 is a reliable irregular shaped silica gel carriers with reversed phase properties. It is well suited for the separation of neutral, acidic and weak basic compounds.This sorbent is packed into a Hibar 125-4 HPLC column. For mounting of a LiChroCART 4-4 guard column, the guard column holder 1.51487 has to be used.

Application

• Determination of amphotericin B, liposomal amphotericin B, and amphotericin B colloidal dispersion in plasma by high-performance liquid chromatography.: This study by Egger et al. focuses on the HPLC determination of various forms of amphotericin B in plasma, utilizing LiChrosorb^® RP-8 as the stationary phase. This method ensures accurate monitoring of these antifungal agents in clinical settings (Egger et al., 2001).


• Determination of peptide hydrophobicity parameters by reversed-phase high-performance liquid chromatography.: This research by Rothemund et al. used LiChrosorb^® RP-8 to determine the hydrophobicity of various peptides, providing valuable insights for peptide characterization in biochemical research (Rothemund et al., 1994).


• HPLC determination of doxorubicin, doxorubicinol and four aglycone metabolites in plasma of AIDS patients.: Beijnen et al. employed LiChrosorb^® RP-8 in an HPLC method to quantify doxorubicin and its metabolites in plasma, offering a robust tool for therapeutic drug monitoring in AIDS patients (Beijnen et al., 1991).

Analysis Note

Pressure: ≤ 50 bar
Theoretical Plates (N/m) (Toluene): ≥ 55000
Symmetry (Toluene): 0.8 - 1.4
Capacity factor (Toluene): 0.5 - 1.5

Legal Information

Hibar is a registered trademark of Merck KGaA, Darmstadt, Germany

LiChrosorb is a registered trademark of Merck KGaA, Darmstadt, Germany